Suchergebnisse - "Reverse Transcriptase Inhibitors/adverse effects"

Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort

Autoren: Hirschel, B. Flepp, M. Bucher, H. C. et al.

Schlagwörter: Adult CD4 Lymphocyte Count Case-Control Studies Cohort Studies Drug Tolerance Female HIV Infections/complications/*drug therapy/immunology/virology HIV Protease Inhibitors/adverse effects/*therapeutic use HIV-1/drug effects/isolation & purification Humans Male Oxazines/adverse effects/*therapeutic use RNA, Viral/blood Reverse Transcriptase Inhibitors/adverse effects/*therapeutic use Substance Abuse, Intravenous/complications Switzerland

Relation: AIDS; https://iris.unil.ch/handle/iris/36387; serval:BIB_016EC29FEF40; 000173929900009

Verfügbarkeit: https://iris.unil.ch/handle/iris/36387
https://doi.org/10.1097/00002030-200202150-00009

Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study

Autoren: Bassetti, S. Battegay, M. Furrer, H. et al.

Schlagwörter: Anti-HIV Agents/adverse effects/*therapeutic use CD4 Lymphocyte Count Cohort Studies Cross-Sectional Studies Drug Therapy, Combination Drug Utilization Education Female Guideline Adherence HIV Infections/*drug therapy/psychology HIV Protease Inhibitors/adverse effects/therapeutic use Humans Male Patient Compliance/psychology *Physician's Practice Patterns *Prescriptions, Drug Reverse Transcriptase Inhibitors/adverse effects/therapeutic use Risk Factors Substance Abuse, Intravenous Switzerland Treatment Refusal/psychology

Relation: Journal of Acquired Immune Deficiency Syndrome; https://iris.unil.ch/handle/iris/254952; serval:BIB_E379FE6C804E; 000080647500006

Verfügbarkeit: https://iris.unil.ch/handle/iris/254952

The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study.

Autoren: Young, J. Scherrer, A.U. Calmy, A. et al.

Weitere Verfasser: Young, J. Scherrer, A.U. Calmy, A. et al.

Schlagwörter: Adult, Aged, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Cohort Studies, Female, HIV Infections/drug therapy, HIV Infections/immunology, HIV Infections/virology, HIV-1/drug effects, Humans, Male, Middle Aged, Randomized Controlled Trials as Topic, Reverse Transcriptase Inhibitors/administration & dosage, Reverse Transcriptase Inhibitors/adverse effects, Reverse Transcriptase Inhibitors/therapeutic use, Treatment Outcome, Viral Load

Relation: Antiviral Therapy; https://iris.unil.ch/handle/iris/247698; serval:BIB_EE3F2AF63928; 000525652500003

Verfügbarkeit: https://iris.unil.ch/handle/iris/247698
https://doi.org/10.3851/IMP3310

Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study

Autoren: Young, J. Rickenbach, M. Weber, R. et al.

Schlagwörter: Adipose Tissue/*drug effects/*pathology Adult Antiretroviral Therapy, Highly Active/adverse effects Cohort Studies Female HIV Infections/*drug therapy/*pathology HIV Protease Inhibitors/*adverse effects HIV-Associated Lipodystrophy Syndrome/etiology/pathology Humans Male Middle Aged Reverse Transcriptase Inhibitors/*adverse effects Risk Factors Stavudine/adverse effects Switzerland

Relation: Antiviral Therapy; https://iris.unil.ch/handle/iris/245542; serval:BIB_F234AB2FD71E; 000231962100007

Verfügbarkeit: https://iris.unil.ch/handle/iris/245542

Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.

Autoren: Young, J. Schäfer, J. Fux, C.A. et al.

Weitere Verfasser: Young, J. Schäfer, J. Fux, C.A. et al.

Schlagwörter: Adenine/adverse effects, Adenine/analogs & derivatives, Adult, Benzoxazines/adverse effects, Drug Therapy, Combination/adverse effects, Combination/methods, Female, Glomerular Filtration Rate/drug effects, HIV Infections/drug therapy, HIV Protease Inhibitors/administration & dosage, HIV Protease Inhibitors/adverse effects, Humans, Kidney/drug effects, Kidney/physiopathology, Lopinavir/adverse effects, Male, Middle Aged, Oligopeptides/adverse effects, Organophosphonates/adverse effects, Pyridines/adverse effects, Reverse Transcriptase Inhibitors/administration & dosage, Reverse Transcriptase Inhibitors/adverse effects, Ritonavir/adverse effects, Treatment Outcome

Relation: AIDS; https://iris.unil.ch/handle/iris/242272; serval:BIB_E49D4C7F0E9D; 000301333000006

Verfügbarkeit: https://iris.unil.ch/handle/iris/242272
https://doi.org/10.1097/QAD.0b013e32834f337c

Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy.

Autoren: Young, J. Glass, T.R. Bernasconi, E. et al.

Weitere Verfasser: Young, J. Glass, T.R. Bernasconi, E. et al.

Schlagwörter: Adult, Anti-HIV Agents/adverse effects, Anti-Retroviral Agents/adverse effects, Antiretroviral Therapy, Highly Active/adverse effects, Female, HIV Infections/complications, HIV Infections/drug therapy, HIV Protease Inhibitors/adverse effects, Humans, Male, Metabolic Syndrome X/chemically induced, Models, Statistical, Oligopeptides/adverse effects, Prospective Studies, Pyridines/adverse effects, Reverse Transcriptase Inhibitors/adverse effects, Risk Factors, Stavudine/adverse effects, Switzerland

Relation: Journal of Clinical Epidemiology; https://iris.unil.ch/handle/iris/180918; serval:BIB_DADAFC5F4F9A; 000266291600013

Verfügbarkeit: https://iris.unil.ch/handle/iris/180918
https://doi.org/10.1016/j.jclinepi.2008.07.015

In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.

Autoren: Aouri, M. Barcelo, C. Ternon, B. et al.

Weitere Verfasser: Aouri, M. Barcelo, C. Ternon, B. et al.

Schlagwörter: Anti-HIV Agents/adverse effects, Anti-HIV Agents/blood, %22">Anti-HIV Agents/ , Benzoxazines/adverse effects, Benzoxazines/blood, %22">Benzoxazines/ , Cytochrome P-450 CYP2A6/genetics, Cytochrome P-450 CYP2A6/metabolism, Cytochrome P-450 CYP2B6/genetics, Cytochrome P-450 CYP2B6/metabolism, Cytochrome P-450 CYP3A/genetics, Cytochrome P-450 CYP3A/metabolism, Genotype, Glucuronides/blood, Glucuronides/cerebrospinal fluid, HIV Infections/diagnosis, HIV Infections/drug therapy, Humans, Hydroxylation, Metabolic Detoxication, Phase I, Phase II, Metabolomics/methods, Neurotoxicity Syndromes/etiology, Neurotoxicity Syndromes/genetics, Phenotype, Reverse Transcriptase Inhibitors/adverse effects, Reverse Transcriptase Inhibitors/blood, %22">Reverse Transcriptase Inhibitors/ , Risk Assessment

Relation: Drug Metabolism and Disposition; https://iris.unil.ch/handle/iris/110473; serval:BIB_4B30049F72DE; 000366657900016

Verfügbarkeit: https://iris.unil.ch/handle/iris/110473
https://doi.org/10.1124/dmd.115.065839

Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study

Autoren: Young, J. Weber, R. Rickenbach, M. et al.

Schlagwörter: Antiretroviral Therapy, Highly Active Cohort Studies Drug Therapy, Combination Female HIV Infections/blood/*drug therapy HIV Protease Inhibitors/adverse effects/*therapeutic use Humans Hyperlipidemias/blood/etiology Lipids/*blood Male Prospective Studies Reverse Transcriptase Inhibitors/adverse effects/*therapeutic use Ritonavir/*pharmacology Switzerland Triglycerides/blood

Relation: Antiviral Therapy; https://iris.unil.ch/handle/iris/103275; serval:BIB_2CA99B7FC263; 000231963400001

Verfügbarkeit: https://iris.unil.ch/handle/iris/103275

Efavirenz decreases methadone blood concentrations.

Autoren: Marzolini, C. Troillet, N. Telenti, A. et al.

Schlagwörter: Adult, Anti-HIV Agents/therapeutic use, Benzoxazines, Drug Interactions, Female, HIV Infections/blood, HIV Infections/drug therapy, Humans, Lamivudine/therapeutic use, Methadone/blood, Methadone/pharmacokinetics, Oxazines/adverse effects, Oxazines/therapeutic use, Reverse Transcriptase Inhibitors/adverse effects, Reverse Transcriptase Inhibitors/therapeutic use, Stavudine/therapeutic use, Substance Withdrawal Syndrome

Relation: AIDS; https://iris.unil.ch/handle/iris/103145; serval:BIB_3264B6C2D4B7; 000087735700036

Verfügbarkeit: https://iris.unil.ch/handle/iris/103145
https://doi.org/10.1097/00002030-200006160-00036

Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis

Autoren: Jesson, Julie Saint-Lary, Laura Revegue, Marc Harris Dassi Tchoupa et al.

Weitere Verfasser: Jesson, Julie Saint-Lary, Laura Revegue, Marc Harris Dassi Tchoupa et al.

Quelle: ISSN: 2352-4642.

Schlagwörter: MESH: Adolescent, MESH: Adult, MESH: Nucleosides / therapeutic use, MESH: Observational Studies as Topic, MESH: Prospective Studies, MESH: Retrospective Studies, MESH: Reverse Transcriptase Inhibitors / adverse effects, MESH: Anti-HIV Agents / adverse effects, MESH: Child, MESH: Cross-Sectional Studies, MESH: Cyclopropanes, MESH: Dideoxyadenosine / analogs & derivatives, MESH: HIV Infections* / drug therapy, MESH: Humans, MESH: Infant, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie

Relation: info:eu-repo/semantics/altIdentifier/pmid/36058225; PUBMED: 36058225; PUBMEDCENTRAL: PMC9474298

Verfügbarkeit: https://hal.science/hal-04229141
https://hal.science/hal-04229141v1/document
https://hal.science/hal-04229141v1/file/Jesson_Lancet%20version%20auteur2.pdf
https://doi.org/10.1016/S2352-4642(22)00213-9

Individualising HIV treatment--pharmacogenetics and immunogenetics

Autoren: Telenti, A. Aubert, V. Spertini, F.

Schlagwörter: Anti-HIV Agents/*adverse effects/therapeutic use Dideoxynucleosides/*adverse effects/therapeutic use Drug Hypersensitivity/*genetics/immunology Genetic Screening HIV Infections/*drug therapy/genetics/immunology Haplotypes Humans Major Histocompatibility Complex/genetics Reverse Transcriptase Inhibitors/*adverse effects/therapeutic use

Relation: The Lancet; https://iris.unil.ch/handle/iris/53081; serval:BIB_45D2B6BF0F87; 000174115200002

Verfügbarkeit: https://iris.unil.ch/handle/iris/53081
https://doi.org/10.1016/S0140-6736(02)07899-6

Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor–Based Combination Antiretroviral Therapy: The D A D Study

Autoren: Bruyand, Mathias Ryom, Lene Shepherd, Leah et al.

Quelle: JAIDS : Journal of Acquired Immune Deficiency Syndromes, 68, 5, pp. 568-77
Bruyand, M, Ryom, L, Shepherd, L, Fatkenheuer, G, Grulich, A, Reiss, P, de Wit, S, D Arminio Monforte, A, Furrer, H, Pradier, C, Lundgren, J, Sabin, C, D:A:D Study Group & Friis-Møller, N 2015, ' Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy : the D: A: D study ', J A I D S, vol. 68, no. 5, pp. 568-577 . https://doi.org/10.1097/QAI.0000000000000523

Schlagwörter: EMC MM-04-54-08-A, Male, Lymphoma, antiretroviral therapy, cancer, HIV, risk, Protease Inhibitor, 32 Biomedical and Clinical Sciences, HIV Infections, anzsrc-for: 4202 Epidemiology, Pharmacologie, Cancer risk, Protease Inhibitor, Nonnucleoside Reverse Transcriptase Inhibitor, Antiretroviral therapy, HIV, anzsrc-for: 1103 Clinical Sciences, Cancer risk, 0302 clinical medicine, Antiretroviral Therapy, Highly Active, Neoplasms, Prospective Studies, Pathologie maladies infectieuses, Middle aged, Cancer, Risk assessment, Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences, anzsrc-for: 42 Health Sciences, Protease inhibitors - adverse effects, Incidence, highly active - adverse effects, Hematology, Neoplasms - epidemiology, Middle Aged, Antiretroviral therapy, 3. Good health, Infectious Diseases, anzsrc-for: 3202 Clinical sciences, HIV/AIDS, Reverse Transcriptase Inhibitors, Female, Adult, Follow-Up Studies, Humans, Protease Inhibitors, Risk Assessment, Pharmacology (medical), Medicine (all), anzsrc-for: 1117 Public Health and Health Services, Lymphatic Research, highly active - methods, anzsrc-for: 4206 Public health, Antiretroviral Therapy, Follow-up studies, 03 medical and health sciences, Rare Diseases, anzsrc-for: 32 Biomedical and Clinical Sciences, EMC MM-04-28-04, SDG 3 - Good Health and Well-being, Clinical Research, D:A:D study group, Genetics, Highly Active, Nonnucleoside Reverse Transcriptase Inhibitor, HIV infections - drug therapy, anzsrc-for: 3211 Oncology and Carcinogenesis, Reverse transcriptase inhibitors - adverse effects, 42 Health Sciences, 3211 Oncology and Carcinogenesis, Sexually Transmitted Infections, Digestive Diseases, Prospective studies

Dateibeschreibung: application/pdf; No full-text files

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/25763785
https://www.bib.irb.hr/892785
https://doi.org/10.1097/qai.0000000000000523
https://cris.maastrichtuniversity.nl/en/publications/1584259b-5d6a-47b1-a5ea-b10f566b02df
https://doi.org/10.1097/QAI.0000000000000523
https://boris.unibe.ch/65536/
http://findresearcher.sdu.dk/portal/da/publications/cancer-risk-and-use-of-protease-inhibitor-or-nonnucleoside-reverse-transcriptase-inhibitorbased-combination-antiretroviral-therapy(99abd96b-1af9-4852-9e1c-cd76d6a6b58c).html
https://boa.unimib.it/handle/10281/96655
https://pubmed.ncbi.nlm.nih.gov/25763785/
https://researchrepository.murdoch.edu.au/id/eprint/38820/
https://www.narcis.nl/publication/RecordID/oai%3Arepository.ubn.ru.nl%3A2066%2F154699
http://journals.lww.com/jaids/pages/default.aspx
https://hdl.handle.net/11564/644473
https://doi.org/10.1097/QAI.0000000000000523
http://hdl.handle.net/2066/154699
https://doi.org/10.1097/QAI.0000000000000523
http://journals.lww.com/jaids/pages/default.aspx
https://doi.org/10.1097/QAI.0000000000000523
https://hdl.handle.net/10281/96655
https://portal.findresearcher.sdu.dk/da/publications/99abd96b-1af9-4852-9e1c-cd76d6a6b58c
https://portal.findresearcher.sdu.dk/da/publications/99abd96b-1af9-4852-9e1c-cd76d6a6b58c
https://doi.org/10.1097/QAI.0000000000000523
http://journals.lww.com/jaids/pages/default.aspx
https://doi.org/10.1097/QAI.0000000000000523
https://hdl.handle.net/11379/478869
https://journals.lww.com/jaids/Fulltext/2015/04150/Cancer_Risk_and_Use_of_Protease_Inhibitor_or.13.aspx
https://doi.org/10.1097/QAI.0000000000000523
https://hdl.handle.net/11392/2417062
http://journals.lww.com/jaids/pages/default.aspx
https://doi.org/10.1097/QAI.0000000000000523
https://hdl.handle.net/2318/1574300

Assessment of Bone Mineral Density in Tenofovir-Treated Patients With Chronic Hepatitis B: Can the Fracture Risk Assessment Tool Identify Those at Greatest Risk?

Autoren: GILL, US Zissimopoulos, A Al-Shamma, S et al.

Quelle: Journal of Infectious Diseases. 211:374-382

Schlagwörter: Adult, Male, Risk, 0301 basic medicine, Hepatitis B virus, DEXA, Reverse Transcriptase Inhibitors/adverse effects, Organophosphonates, Chronic/drug therapy, Risk Assessment, Body Mass Index, 03 medical and health sciences, Hepatitis B, Chronic, Bone Density, Organophosphonates/adverse effects, Humans, chronic hepatitis B, Risk Assessment/methods, Tenofovir, 2. Zero hunger, 0303 health sciences, Adenine, Bone Density/drug effects, Middle Aged, Hepatitis B, tenofovir, 3. Good health, Hepatitis B virus/drug effects, Cross-Sectional Studies, Adenine/adverse effects, Reverse Transcriptase Inhibitors, Female, chronic hepatitis, bone mineral density, FRAX

Zugangs-URL: https://academic.oup.com/jid/article-pdf/211/3/374/13805845/jiu471.pdf
https://pubmed.ncbi.nlm.nih.gov/25156561
https://www.natap.org/2014/HIV/J2015-Gill-374-82.pdf
https://academic.oup.com/jid/article/211/3/374/2912189
http://qmro.qmul.ac.uk/xmlui/handle/123456789/9840
https://pubmed.ncbi.nlm.nih.gov/25156561/
http://jid.oxfordjournals.org/content/early/2014/10/03/infdis.jiu471.full
http://www.natap.org/2014/HIV/J2015-Gill-374-82.pdf

Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis

Autoren: Ford, Nathan Mofenson, Lynne Shubber, Zara et al.

Quelle: AIDS, Vol. 28 Suppl 2 (2014) pp. S123-31

Schlagwörter: Cyclopropanes, Reverse Transcriptase Inhibitors/adverse effects, HIV Infections/drug therapy, HIV Infections, Central Nervous System Diseases/chemically induced/congenital, 03 medical and health sciences, 0302 clinical medicine, Central Nervous System Diseases, Pregnancy, Abnormalities, Drug-Induced/epidemiology, Humans, Pregnancy Complications, Infectious, ddc:616, Pregnancy Complications, Infectious/drug therapy, Benzoxazines/adverse effects, Abnormalities, Drug-Induced, Infectious Disease Transmission, Vertical, Benzoxazines, 3. Good health, Pregnancy Trimester, First, Treatment Outcome, Alkynes, Reverse Transcriptase Inhibitors, Female, Infectious Disease Transmission, Vertical/prevention & control

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/24849471
https://fieldresearch.msf.org/handle/10144/255366
https://www.who.int/hiv/pub/journal_articles/05_art_efavirenz-safety.pdf
https://www.who.int/iris/bitstream/10665/93526/1/WHO_HIV_2013.53_eng.pdf
https://www.ncbi.nlm.nih.gov/pubmed/24849471
https://journals.lww.com/00002030-201111280-00013
https://insights.ovid.com/article/00002030-201403002-00005
https://archive-ouverte.unige.ch/unige:74400

No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial*

Autoren: Mark Bloch Bernard Hirschel Robert Finlayson et al.

Quelle: HIV Medicine, Vol. 11, No 8 (2010) pp. 493-501

Schlagwörter: Adult, Male, Reverse Transcriptase Inhibitors/adverse effects, Ritonavir/therapeutic use, Anti-Retroviral Agents/adverse effects/*therapeutic use, Adiposity/drug effects, HIV Infections, Pyrimidinones, Pyrimidinones/therapeutic use, Lopinavir, Pravastatin/pharmacokinetics/pharmacology/*therapeutic use, 03 medical and health sciences, Absorptiometry, Photon, 0302 clinical medicine, Humans, Uridine, Adiposity, Pravastatin, ddc:616, Ritonavir, Anticholesteremic Agents, HIV-Associated Lipodystrophy Syndrome, Uridine/pharmacokinetics/pharmacology/*therapeutic use, Extremities, Middle Aged, HIV-Associated Lipodystrophy Syndrome/chemically induced/*drug therapy, Dideoxynucleosides, 3. Good health, Anti-Retroviral Agents, Dideoxynucleosides/adverse effects, Reverse Transcriptase Inhibitors, Drug Therapy, Combination, HIV Infections/complications/drug therapy, Anticholesteremic Agents/pharmacokinetics/pharmacology/*therapeutic use

Dateibeschreibung: application/pdf

Zugangs-URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1468-1293.2009.00817.x
https://pubmed.ncbi.nlm.nih.gov/20236365
https://onlinelibrary.wiley.com/doi/full/10.1111/j.1468-1293.2009.00817.x
https://core.ac.uk/display/60829548
https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1468-1293.2009.00817.x
https://archive-ouverte.unige.ch/unige:20818
https://www.cabdirect.org/cabdirect/abstract/20103257539
https://archive-ouverte.unige.ch/unige:20818
https://archive-ouverte.unige.ch/unige:20818
https://doi.org/10.1111/j.1468-1293.2009.00817.x

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration: a multi-cohort collaboration

Autoren: Sabin, C Worm, S Weber, R et al.

Weitere Verfasser: Sabin, C Worm, S Weber, R et al.

Quelle: The Lancet (London), 371, 9622, pp. 1417-26

Schlagwörter: Adult, Male, HIV Infections -- drug therapy, Myocardial Infarction, 610 Medicine & health, N4i 1: Pathogenesis and modulation of inflammation, HIV Infections, 2700 General Medicine, 10234 Clinic for Infectious Diseases, Risk Factors, 80 and over, Humans, Poisson Distribution, Pathologie maladies infectieuses, Aged, Aged, 80 and over, Didanosine, Dideoxynucleosides, Female, Middle Aged, Reverse Transcriptase Inhibitors, Medicine (all), Myocardial Infarction -- chemically induced, Dideoxynucleosides -- adverse effects -- therapeutic use, Sciences bio-médicales et agricoles, Reverse Transcriptase Inhibitors -- adverse effects -- therapeutic use, 3. Good health, Didanosine -- adverse effects -- therapeutic use, UMCN 4.1: Microbial pathogenesis and host defense

Dateibeschreibung: application/pdf; 1 full-text file(s): application/pdf

Zugangs-URL: https://europepmc.org/articles/pmc2688660?pdf=render
https://pubmed.ncbi.nlm.nih.gov/18387667
https://pubmed.ncbi.nlm.nih.gov/18387667/
https://experts.umn.edu/en/publications/use-of-nucleoside-reverse-transcriptase-inhibitors-and-risk-of-my-2
https://iris.unibs.it/handle/11379/47889
https://www.ncbi.nlm.nih.gov/pubmed/18387667
https://researchrepository.murdoch.edu.au/id/eprint/14884/
https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F466ea608-53ab-4c23-92d2-19699a55d297
http://www.journals.elsevier.com/the-lancet/
https://doi.org/10.1016/S0140-6736(08)60423-7
https://hdl.handle.net/20.500.11768/68458
http://hdl.handle.net/2066/185792
http://www.journals.elsevier.com/the-lancet/
https://hdl.handle.net/10447/215307
https://doi.org/10.1016/S0140-6736(08)60423-7
https://hdl.handle.net/11573/85781
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000255440600022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=0c7ff228ccbaaa74236f48834a34396a
https://doi.org/10.1016/s0140-6736(08)60423-7

Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use

Autoren: Christl A. Donnelly Roy M. Anderson Richard A. Rode et al.

Quelle: Kwong, G P S, Ghani, A C, Rode, R A, Bartley, L M, Cowling, B J, Da Silva, B, Donnelly, C A, Van Sighem, A I, Cameron, D W, Danner, S A, De Wolf, F & Anderson, R M 2006, 'Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use', AIDS, vol. 20, no. 15, pp. 1941-1950. https://doi.org/10.1097/01.aids.0000247115.81832.a1

Schlagwörter: Adult, Male, Time Factors, Adolescent, Antiretroviral Therapy, HIV Infections, Atherosclerosis - chemically induced - mortality, Cohort Studies, 03 medical and health sciences, Sex Factors, 0302 clinical medicine, Risk Factors, Chemicals And Cas Registry Numbers, Antiretroviral Therapy, Highly Active, 80 and over, Humans, Highly Active, Aged, Proportional Hazards Models, Aged, 80 and over, HIV Protease Inhibitors - adverse effects - therapeutic use, Smoking, Age Factors, HIV, HIV Protease Inhibitors, Middle Aged, Cardiovascular disease, Atherosclerosis, Competing risks, Anti-Retroviral Agents - adverse effects - therapeutic use, Antiretroviral therapy, 3. Good health, Reverse Transcriptase Inhibitors - adverse effects - therapeutic use, Myocardial infarction, HIV Infections - complications - drug therapy - mortality, Anti-Retroviral Agents, HIV-1, Reverse Transcriptase Inhibitors, Female

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/16988515
http://hub.hku.hk/handle/10722/92609
https://research.vumc.nl/en/publications/comparison-of-the-risks-of-atherosclerotic-events-versus-death-fr
https://www.ncbi.nlm.nih.gov/pubmed/16988515
https://journals.lww.com/00002030-200610030-00006
https://core.ac.uk/display/37920167
https://www.narcis.nl/publication/RecordID/oai%3Apure.atira.dk%3Apublications%2F4d6e5bcd-ddac-44b2-9c7c-69c60485c036
https://research.vumc.nl/en/publications/4d6e5bcd-ddac-44b2-9c7c-69c60485c036
http://hdl.handle.net/10722/92609

Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort

Autoren: Calmy, Alexandra Pinoges, Lorextu Szumilin, Elisabeth et al.

Quelle: AIDS. 20:1163-1169

Schlagwörter: Anti-HIV Agents / therapeutic use, Adult, Male, Lamivudine / therapeutic use, Anti-HIV Agents, Lamivudine / adverse effects, Medically Underserved Area, Stavudine / therapeutic use, HIV Infections, Antiretroviral Therapy, Highly Active / methods, Drug Administration Schedule, Drugs, Generic / administration & dosage, 03 medical and health sciences, Nevirapine / therapeutic use, 0302 clinical medicine, Antiretroviral Therapy, Highly Active, Reverse Transcriptase Inhibitors / adverse effects, Antiretroviral Therapy, Highly Active / adverse effects, Drugs, Generic, Humans, Nevirapine, Stavudine / administration & dosage, Nevirapine / adverse effects, Developing Countries, Reverse Transcriptase Inhibitors / therapeutic use, HIV Infections / drug therapy, Lamivudine / administration & dosage, CD4 Lymphocyte Count, 3. Good health, Reverse Transcriptase Inhibitors / administration & dosage, Drugs, Generic / therapeutic use, Stavudine, Treatment Outcome, Drugs, Generic / adverse effects, Nevirapine / administration & dosage, Lamivudine, Stavudine / adverse effects, Reverse Transcriptase Inhibitors, Female, Epidemiologic Methods, Anti-HIV Agents / adverse effects, Anti-HIV Agents / administration & dosage

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/16691068
http://core.ac.uk/display/9416695
http://journals.lww.com/00002030-200605120-00010
https://europepmc.org/article/MED/16691068
http://fieldresearch.msf.org/msf/handle/10144/18315
http://fieldresearch.msf.org/msf/bitstream/10144/18315/1/calmy.pdf
https://archive-ouverte.unige.ch/unige:173154
https://doi.org/10.1097/01.aids.0000226957.79847.d6

Lipid Profiles for Antiretroviral-Naive Patients Starting Pi- and Nnrti-Based Therapy in the Swiss HIV Cohort Study

Autoren: Jim Young Rainer Weber Martin Rickenbach et al.

Quelle: Antiviral Therapy, Vol. 10, No 5 (2005) pp. 585-591

Schlagwörter: Male, HIV Infections, Hyperlipidemias, Cohort Studies, Ritonavir/ pharmacology, 03 medical and health sciences, Lipids/ blood, 0302 clinical medicine, Antiretroviral Therapy, Highly Active, Reverse Transcriptase Inhibitors/adverse effects/ therapeutic use, Humans, Prospective Studies, Triglycerides, ddc:616, Hyperlipidemias/blood/etiology, Ritonavir, HIV Protease Inhibitors, Lipids, 3. Good health, HIV Protease Inhibitors/adverse effects/ therapeutic use, Triglycerides/blood, Reverse Transcriptase Inhibitors, Drug Therapy, Combination, Female, Switzerland, HIV Infections/blood/ drug therapy

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/16152752
https://serval.unil.ch/notice/serval:BIB_2CA99B7FC263
https://pubmed.ncbi.nlm.nih.gov/16152752/
https://www.ncbi.nlm.nih.gov/pubmed/16152752
http://www.intmedpress.com/serveFile.cfm?sUID=a46875a8-a7ff-4313-bb0b-25e40cdf459c
https://www.intmedpress.com/serveFile.cfm?sUID=a46875a8-a7ff-4313-bb0b-25e40cdf459c
https://boris.unibe.ch/25707/
https://archive-ouverte.unige.ch/unige:7713

Body Fat Changes among Antiretroviral-Naive Patients on Pi- and Nnrti-Based Haart in the Swiss HIV Cohort Study

Autoren: Jim Young Martin Rickenbach Rainer Weber et al.

Quelle: Antiviral Therapy, Vol. 10, No 1 (2005) pp. 73-81

Schlagwörter: Adult, Male, HIV Infections, HIV Infections/ drug therapy/ pathology, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Adipose Tissue/ drug effects/ pathology, Risk Factors, Antiretroviral Therapy, Highly Active/adverse effects, Reverse Transcriptase Inhibitors/ adverse effects, Antiretroviral Therapy, Highly Active, Humans, HIV Protease Inhibitors/ adverse effects, ddc:616, HIV-Associated Lipodystrophy Syndrome, HIV Protease Inhibitors, Middle Aged, Stavudine/adverse effects, 3. Good health, Stavudine, Adipose Tissue, Reverse Transcriptase Inhibitors, Female, HIV-Associated Lipodystrophy Syndrome/etiology/pathology, Switzerland

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/15751765
https://www.infekt.ch/content/uploads/2013/11/Young_2005_IMP.pdf
https://journals.sagepub.com/doi/10.1177/135965350501000105?icid=int.sj-abstract.similar-articles.3
https://archive-ouverte.unige.ch/unige:7712
http://www.infekt.ch/content/uploads/2013/11/Young_2005_IMP.pdf
https://boris.unibe.ch/25714/
https://archive-ouverte.unige.ch/unige:7712